drugset / Trial / NCT00044681
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
Phase 3
Completed
258 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen, LP · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as augmentation therapy compared with placebo augmentation in these patients.
Timeline
- Start
- 2002-10
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 0.25 mg | Oral |
| Subject | Risperidone | Other / unclassified | 0.5 mg | Oral |
| Subject | Risperidone | Other / unclassified | 1 mg | Oral |
| Subject | Risperidone | Other / unclassified | 2 mg | Oral |